Request Demo

Last update 12 Mar 2026

Ipilimumab biosimilar (Cornerstone)

Last update 12 Mar 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Biosimilar, Monoclonal antibody

Synonyms

Ipilimumab Biosimilar (Cornerstone Pharmaceutical Co., Ltd), 伊匹木单抗生物类似药（基石药业（苏州）有限公司）, CS 1002

+ [4]

Target

CTLA4

Action

inhibitors

Mechanism

CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors)

Therapeutic Areas

NeoplasmsDigestive System DisordersRespiratory Diseases+ [2]

Active Indication

Advanced biliary tract cancerLocally Advanced Lung Non-Small Cell Carcinomametastatic non-small cell lung cancer+ [20]

Inactive Indication-

Originator Organization

Cornerstone Pharmaceutical Co., Ltd

Active Organization

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Shanghai Shengdi Pharmaceutical Co., Ltd.

Shanghai Hengrui Pharmaceutical Co., Ltd.

+ [1]

Inactive Organization

CStone Pharmaceuticals Co. Ltd.

License Organization

Cornerstone Pharmaceutical Co., Ltd

Wuxi Biologics (Shanghai) Co., Ltd.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Structure/Sequence

Sequence Code 143797L

The sequence is quoted from: *****

Sequence Code 9060585H

The sequence is quoted from: *****

Clinical Trials associated with Ipilimumab biosimilar (Cornerstone)

NCT07454720

/ Not yet recruitingPhase 2/3

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Clinical Study of Adebrelimab Combined With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Resectable Rectal Cancer

The study is being conducted to evaluate the safety and efficacy of Adebrelimab and SHR-8068 in combination with chemoradiotherapy in subjects with rectal cancer

Start Date01 Mar 2026

Sponsor / Collaborator

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

NCT07266025

/ Not yet recruitingPhase 2IIT

Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma：A Randomized, Non-comparative Phase 2 Study

This is a randomized, non-comparative, open-label, two-arm phase II clinical trial designed to evaluate the efficacy and safety of neoadjuvant therapy with adebrelimab plus induction chemotherapy versus adebrelimab plus SHR-8086 in patients with dMMR/MSI-H gastric or gastroesophageal junction adenocarcinoma.

Start Date30 Jan 2026

Sponsor / Collaborator-

NCT07229625

/ RecruitingPhase 3

A Phase III, Randomized, Controlled, Open-Label, Multicenter Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-Line Treatment for Advanced Biliary Tract Cancer (BTC)

This study is a randomized, open-label, multicenter phase III clinical trial, aiming to evaluate the efficacy and safety of SHR-8068 combined with adbelimab and platinum-based chemotherapy in contrast to varicumab combined with platinum-based chemotherapy in the first-line treatment of patients with advanced BTC.

Start Date21 Jan 2026

Sponsor / Collaborator

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

100 Clinical Results associated with Ipilimumab biosimilar (Cornerstone)

100 Translational Medicine associated with Ipilimumab biosimilar (Cornerstone)

100 Patents (Medical) associated with Ipilimumab biosimilar (Cornerstone)

Literatures (Medical) associated with Ipilimumab biosimilar (Cornerstone)

01 Jun 2024·Cancer

Dual CTLA‐4 and PD‐1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first‐in‐human, dose‐escalation, and dose‐expansion study

Article

Author: Kotasek, Dusan ; Ma, Yiding ; Aghmesheh, Morteza ; Chan, Stephen L. ; Cosman, Rasha ; Zielinski, Robert ; Mant, Andrew ; Bishnoi, Sarwan ; Moore, Maggie ; Li, Peiqi ; Tse, Archie N. ; Pan, Zhaoxuan ; Prawira, Amy ; Yau, Thomas ; Su, Rila ; Eek, Richard ; Li, Fei

Abstract:

Background:

This study investigated the safety and efficacy of an anti–CTLA‐4 monoclonal antibody (CS1002) as monotherapy and in combination with an anti–PD‐1 monoclonal antibody (CS1003) in patients with advanced/metastatic solid tumors.

Methods:

The phase 1 study involved phase 1a monotherapy dose‐escalation (part 1) and phase 1b combination therapy dose escalation (part 2) and expansion (part 3). Various dosing schedules of CS1002 (0.3, 1, or 3 mg/kg every 3 weeks, or 3 mg/kg every 9 weeks) were evaluated with 200 mg CS1003 every 3 weeks in part 3.

Results:

Parts 1, 2, and 3 included a total of 13, 18, and 61 patients, respectively. No dose‐limiting toxicities or maximum tolerated doses were observed. Treatment‐related adverse events (TRAEs) were reported in 30.8%, 83.3%, and 75.0% of patients in parts 1, 2, and 3, respectively. Grade ≥3 TRAEs were experienced by 15.4%, 50.0%, and 18.3% of patients in each part. Of 61 patients evaluable for efficacy, 23 (37.7%) achieved objective responses in multiple tumor types. Higher objective response rates were observed with conventional and high‐dose CS1002 regimens (1 mg/kg every 3 weeks or 3 mg/kg every 9 weeks) compared to low‐dose CS1002 (0.3 mg/kg every 3 weeks) in microsatellite instability‐high/mismatch repair‐deficient tumors, melanoma, and hepatocellular carcinoma (50.0% vs. 58.8%, 14.3% vs. 42.9%, and 0% vs. 16.7%).

Conclusion:

CS1002, as monotherapy, and in combination with CS1003, had a manageable safety profile across a broad dosing range. Promising antitumor activities were observed in patients with immune oncology (IO)‐naive and IO‐refractory tumors across CS1002 dose levels when combined with CS1003, supporting further evaluation of this treatment combination for solid tumors.

Plain Language Summary:

CS1002 is a human immunoglobulin (Ig) G1 monoclonal antibody that blocks the interaction of CTLA‐4 with its ligands and increases T‐cell activation/proliferation. CS1003, now named nofazinlimab, is a humanized, recombinant IgG4 monoclonal antibody that blocks the interaction between human PD‐1 and its ligands.In this original article, we determined the safety profile of CS1002 as monotherapy and in combination with CS1003. Furthermore, we explored the antitumor activity of the combination in anti–programmed cell death protein (ligand)‐1 (PD‐[L]1)‐naive microsatellite instability‐high/mismatch repair‐deficient (MSI‐H/dMMR) pan tumors, and anti–PD‐(L)1‐refractory melanoma and hepatocellular carcinoma (HCC).CS1002 in combination with CS1003 had manageable safety profile across a broad dosing range and showed promising antitumor activities across CS1002 dose levels when combined with CS1003. This supports further assessment of CS1002 in combination with CS1003 for the treatment of solid tumors.

01 Jan 2017·BMJ openQ4 · MEDICINE

Rococo study: a real-world evaluation of an over-the-counter medicine in acute cough (a multicentre, randomised, controlled study)

Q4 · MEDICINE

ArticleOA

Author: Wilson, R ; Brew, J ; Edwards, V ; Kilbourn, A ; Morice, A H ; Birring, S S

Objectives:

To investigate the efficacy and safety of CS1002, an over-the-counter cough treatment containing diphenhydramine, ammonium chloride and levomenthol in a cocoa-based demulcent.

Design:

A multicentre, randomised, parallel group, controlled, single-blinded study in participants with acute upper respiratory tract infection-associated cough.

Setting:

4 general practitioner (GP) surgeries and 14 pharmacies in the UK.

Participants:

Participants aged ≥18 years who self-referred to a GP or pharmacist with acute cough of <7 days' duration. Participant inclusion criterion was cough severity ≥60 mm on a 0–100 mm visual analogue scale (VAS). Exclusion criteria included current smokers or history of smoking within the past 12 months (including e-cigarettes). 163 participants were randomised to the study (mean participant age 38 years, 57% females).

Interventions:

Participants were randomised to CS1002 (Unicough) or simple linctus (SL), a widely used cough treatment, and treatment duration was 7 days or until resolution of cough.

Main outcome measures:

The primary analysis was intention-to-treat (157 participants) and comprised cough severity assessed using a VAS after 3 days' treatment (prespecified primary end point at day 4). Cough frequency, sleep disruption, health status (Leicester Cough Questionnaire (LCQ-acute)) and cough resolution were also assessed.

Results:

At day 4 (primary end point), the adjusted mean difference (95% CI) in cough severity VAS between CS1002 and SL was −5.9 mm (−14.4 to 2.7), p=0.18. At the end of the study (day 7) the mean difference in cough severity VAS was −4.2 mm (−12.2 to 3.9), p=0.31. CS1002 was associated with a greater reduction in cough sleep disruption (mean difference −11.6 mm (−20.6 to 2.7), p=0.01) and cough frequency (mean difference −8.1 mm (−16.2 to 0.1), p=0.05) compared with SL. There was greater improvement in LCQ-acute quality of life scores with CS1002 compared with SL: mean difference (95% CI) 1.2 (0.05 to 2.36), p=0.04 after 5 days' treatment. More participants prematurely stopped treatment due to cough improvement in the CS1002 group (24.4%) compared with SL (10.7%; p=0.02). Adverse events (AEs) were comparable between CS1002 (20.5%) and SL (27.6%) and largely related to the study indication. 6 participants (7%) in the CS1002 group reduced the dose of medication due to drowsiness/tiredness, which subsequently resolved. These events were not reported by participants as AEs.

Conclusions:

Although the primary end point was not achieved, CS1002 was associated with greater reductions in cough frequency, sleep disruption and improved health status compared with SL.

Trial registration number:

EudraCT number 2014-004255-31 .

Frontiers in Immunology

SHR-8068 combined with adebrelimab and bevacizumab in the treatment of refractory advanced colorectal cancer: study protocol for a single-arm, phase Ib/II study

Article

Author: Zhang, Pei ; Wang, Xin ; Yang, Yu ; Wang, Jianfei ; Li, Xiaofen ; Cao, Dan

Background:

The third-line treatment for refractory colorectal cancer (CRC) has limited efficacy. This study aimed to evaluate the safety and efficacy of SHR-8068 (an anti-CTLA-4 antibody), combined with adebrelimab (an anti-PD-L1 antibody), and bevacizumab in refractory non-microsatellite instability-high (MSI-H) or proficient mismatch repair (pMMR) CRC.

Method:

This study is a prospective, open-label, single-center phase Ib/II clinical trial. Patients with pathologically confirmed pMMR/non-MSI-H metastatic colorectal adenocarcinoma who have failed ≥2 lines prior standard systemic treatments will be enrolled (n=36). The Ib phase will evaluate two dosing regimens of SHR-8068 in combination therapy (n=9 each dosage): SHR-8068 (1 mg per kilogram, every six weeks, intravenously) or SHR-8068 (4 mg per kilogram, every twelve weeks, intravenously) combined with adebrelimab (1200 mg, every three weeks, intravenously) and bevacizumab (7.5 mg per kilogram, every three weeks, intravenously). The efficacy and adverse events (AEs) of these regimens will be assessed to determine the recommended phase II dose (RP2D) of SHR-8068. Those of RP2D group from the phase Ib will be included in the phase II. The study will go to include 18 additional patients according to the one-sample log-rank test design in the phase II. The primary endpoint of the Ib phase is safety, with secondary endpoints including the objective response rate (ORR), progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and quality of life (QOL). The primary endpoint for phase II was PFS, with secondary endpoints including ORR, OS, DCR, safety, and QOL. Identifying biomarkers to predict the efficacy of this regimen is the exploratory study endpoint.

Discussion:

This proof-of-concept study would provide safety and efficacy signals of this novel combination treatment for the MSS CRCs in the late-line setting. And it may offer new insights on the clinical application of dual immunotherapy combined with anti-angiogenic therapy in the MSS CRC.

News (Medical) associated with Ipilimumab biosimilar (Cornerstone)

05 Jun 2025

·www.prnewswire.com

Hengrui Pharma Showcases Global Impact at the 2025 ASCO: 72 Study Results Highlight Chinese Cancer Innovation

SHANGHAI, June 5, 2025 /PRNewswire/ -- The 2025 ASCO Annual Meeting successfully concluded in Chicago on June 3 (local time). Hengrui Pharma delivered a strong international presence, featuring 15 innovative drugs and 72 research outcomes. These included 4 oral presentations, 5 rapid oral presentations, 27 poster presentations, and 36 online publications. Multiple groundbreaking research advances has elicited widespread discussion among global experts. In the field of breast cancer, results from 19 studies evaluating the company's innovative drugs—pyrotinib, dalpiciclib, camrelizumab, apatinib, adebrelimab, Trastuzumab rezetecan (SHR-A1811), and SHR-2017, either in combination with each other or with chemotherapies, were presented at ASCO 2025. Notably, 7 studies involving pyrotinib and 6 studies involving dalpiciclib were selected, with both agents consistently demonstrating promising efficacy, reinforcing their established roles in breast cancer treatment. Furthermore, studies evaluating SHR-A1811 and adebrelimab were selected for rapid oral presentations, attracting considerable attention from the industry. In the field of gastrointestinal cancers, drugs such as camrelizumab, apatinib, adebrelimab, and SHR-8068 were featured in a total of 30 accepted studies. Notably, camrelizumab was included in 21 of these studies, demonstrating its broad therapeutic profile and potential while reinforcing its position as a key focus at ASCO. This further solidifies the achievements of China-developed PD-1 inhibitors on the global stage. Additionally, adebrelimab, which has achieved significant breakthroughs in lung cancer in recent years, is actively expanding into new indications. At this year's ASCO, five related studies exploring adebrelimab's efficacy in indications such as hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA) , and pancreatic cancer were presented. The ongoing emergence of cutting-edge research on both established and emerging agents holds promise for improving clinical outcomes for patients with gastrointestinal tumors. Across a wide range of disease areas—including lung cancer, gynecologic cancers, lymphoma, bladder cancer, head and neck cancer, melanoma, sarcoma, nasopharyngeal carcinoma, chordoma, salivary gland cancer, thymic cancer, desmoid tumors, and salivary duct carcinoma—Hengrui Pharma's innovative oncology portfolio (camrelizumab, apatinib, adebrelimab, pyrotinib, dalpiciclib, fluzoparib, famitinib, SHR-A1811, SHR-1501, SHR-1701, SHR-1826, SHR-A1912, and SHR-A2102) was featured in 22 research presentations at ASCO 2025. These comprised 4 oral presentations, 2 rapid oral presentations, 12 poster presentations, and 4 online publications, collectively demonstrating the company's robust R&D capabilities. Additionally, one online publication highlighted ondansetron oral soluble film, underscoring its favorable efficacy in preventing and treating chemotherapy-induced nausea and vomiting (CINV). For 15 consecutive years, Hengrui Pharma has consistently presented its cutting-edge research at the ASCO Annual Meeting, highlighting the company's global leadership in oncology drug research and development while showcasing China's robust pharmaceutical innovation capabilities to the international academic community. The inclusion of 70 Hengrui-sponsored studies at this year's meeting reflects the strong foundation laid by the company's portfolio of 23 marketed innovative drugs and a robust pipeline of over 90 candidates currently in development. Looking ahead, Hengrui will remain committed to its patient-centric approach, striving to develop advanced therapeutics that support the "Healthy China" initiative and enhance clinical outcomes for patients globally. SOURCE Hengrui Pharma WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

ASCOClinical ResultCSCO

22 Nov 2021

·endpts.com

Two of China's top PD-(L)1 players team up on CTLA-4 in $200M deal

Now that the PD-(L)1 craze has (largely) swept through China, resulting in the approval of more than a dozen drugs with more to come, two of the top domestic oncology players are teaming up to go after the other checkpoint target. Hengrui is licensing exclusive China rights to CStone’s CTLA-4 inhibitor, CS1002, in a deal worth up to $200 million, which covers research, development, registration, manufacturing and commercialization. CStone is keeping the rest of world rights to itself — in this case meaning outside “Greater China.” Even though Chinese drug developers have been scouting global partners to co-develop and sell their homegrown drugs outside of China with fervor, tie-ups between local biopharma companies are still uncommon. The PD-(L)1 drugs from Hengrui and CStone have each earned the favor of US-based companies, with Incyte grabbing Hengrui’s camrelizumab as early as 2015 (before ultimately dropping it) and EQRx picking up CStone’s sugemalimab more recently. The new partners note that despite the early discovery of CTLA-4 — Jim Allison and Tasuku Honjo were awarded the Nobel Prize for it — and all the clinical validation of it as an I/O target, only one anti-CTLA-4 antibody has been approved globally (including in China). Without naming Yervoy, they added that the drug made $1.69 billion in 2020. “As a leading global China pharmaceutical company with an extensive oncology pipeline and strong integrated capabilities in commercialization, we are very confident that Hengrui will bring the full potentialities of CS1002 into the Greater China market,” CStone CEO Frank Jiang said in a statement. While CStone has a partnership with Blueprint Medicines to market two of its targeted cancer therapies in China, it does not have any commercial drug of its own. Citing results from an ongoing Phase Ia/Ib study, CStone touted how the combination of CS1002 and CS1003, a PD-1 blocker, was well-tolerated and demonstrated “very encouraging efficacy” in PD-(L)1-refractory melanoma and hepatocellular carcinoma, as well as PD-(L)1-naïve, pretreated microsatellite instability high/deficient mismatch repair (MSI-H/dMMR) tumors. While other CTLA-4 drugs have spurred concerns with toxicity or lack of efficacy, Lianshan Zhang, Hengrui’s president of R&D, expressed faith that CS1002’s “differentiated dosing schedules” will make it a backbone I/O asset.

AntibodyCollaborate

22 Nov 2021

·www.biospace.com

Two Chinese Biopharmas Align in $200 Million IO Deal

CStone Pharmaceuticals continues to expand its oncology presence aimed at the Chinese market. On Sunday, the company forged a licensing agreement with Jiangsu Hengrui Pharmaceuticals that grants the company access to a monoclonal antibody aimed at multiple forms of cancer. Currently, the only anti-CTLA-4 monoclonal antibody that has been approved globally is Bristol Myers Squibb's Yervoy, which was first approved by the U.S. Food and Drug Administration in 2011 and has also been approved for use in China. Yervoy generated approximately $1.69 billion in 2020. Based on its developmental data, CStone believes that CS1002 has the potential to carve away Yervoy’s revenue. CStone licensed CS1002, an investigational anti-CTLA-4 monoclonal antibody to Hengrui. Cytotoxic T lymphocyte associated antigen 4 (CTLA-4) is one of the few clinically validated targets for IO combination therapies. Based on previous preclinical and clinical studies, CStone believes that CS1002 has the potential to become a backbone therapeutic for multiple immuno-oncology combinations. And that evidence was strong enough for Hengrui to pay $200 million in upfront payment for the asset. Under terms of the deal, Hengrui gains the exclusive rights for research, development, manufacturing, and commercialization of CS1002 in Greater China. CStone will retain rights to market CS1002 outside of China. Lianshan Zhang, president of global R&D at Hengrui, said that the combination therapy potential of CS1002 will provide synergy with the company’s existing pipeline and bolster its competitiveness across China. “As a leading Chinese biopharmaceutical company, CStone has demonstrated its outstanding research and development capabilities with impressive early-stage clinical data and differentiated dosing schedules of CS1002. We have full confidence in the future development of it to provide more innovative drugs for Chinese patients,” Zhang said in a statement. Frank Jiang, chairman and chief executive officer of CStone, expressed his satisfaction of the agreement reached with Hengrui. “As a leading global China pharmaceutical company with an extensive oncology pipeline and strong integrated capabilities in commercialization, we are very confident that Hengrui will bring the full potentialities of CS1002 into the Greater China market. Through this collaboration, we believe we will join forces to bring forward more high-quality innovative oncology therapies to patients,” Jiang said in a statement. For CStone, the partnership with Hengrui follows a regulatory win in China for anti-PD-1 therapy. In September, China’s National Medical Products Administration approved the company’s checkpoint inhibitor sugemalimab as consolidation therapy in patients with unresectable stage III non-small-cell lung cancer. The company said the approval marks a first as sugemalimab becomes the “world’s first anti-PD-1/PD-L1 monoclonal antibody to significantly improve progression-free survival in patients with stage III non-small cell lung cancer (NSCLC) without disease progression after concurrent or sequential chemoradiotherapy.” In August, CStone saw the fruits of a partnership with Servier Pharmaceuticals after that company won U.S. approval for Tibsovo (ivosidenib tablets) for the treatment of adult patients with previously treated, locally advanced, or metastatic cholangiocarcinoma with an IDH1 mutation. Tibsovo is the first and only targeted therapy approved for patients with previously treated IDH1-mutated cholangiocarcinoma, a cancer of the bile ducts. CStone is no stranger to working with pharma giants. In 2019, the company partnered with Bayer, and then in 2020, CStone struck a partnership with Pfizer in support of the development of sugemalimab that included the pharma giant taking a $200 million stake in the company.

CollaborateAntibodyInnovative Drug

100 Deals associated with Ipilimumab biosimilar (Cornerstone)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L01XC11	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Rectal Adenocarcinoma	Phase 3	China	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	02 Mar 2026
Rectal Cancer	Phase 3	China	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	02 Mar 2026
Locally Advanced Rectal Carcinoma	Phase 3	China	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	01 Mar 2026
Advanced biliary tract cancer	Phase 3	China	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	08 Jan 2026
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	China	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	22 Oct 2025
metastatic non-small cell lung cancer	Phase 3	China	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	22 Oct 2025
Advanced Hepatocellular Carcinoma	Phase 3	China	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	28 Oct 2024
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma	Phase 3	China	Shanghai Shengdi Pharmaceutical Co., Ltd.	01 Mar 2024
Advanced Renal Cell Carcinoma	Phase 2	China	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	06 Jan 2026
Renal Cell Carcinoma	Phase 2	China	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	18 Dec 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05444088 (ASCO2025) Manual	Phase 1/2	Advanced Hepatocellular Carcinoma Second line \| First line \| Third line	101	SHR-8068 (1 mg/kg Q6W)SHR-8068 (1 mg/kg Q6W) + Adebrelimab + Bevacizumab (Combo 1)	smgxccfptl(pqouvpfpie) = ouxpdksjin qnurdqowqn (nystqetoiq, 13.8 - 50.2) View more	Positive	30 May 2025
				SHR-8068 (4 mg/kg priming)SHR-8068 (4 mg/kg priming) + Adebrelimab + Bevacizumab (Combo 2)	smgxccfptl(pqouvpfpie) = mhhmtpvafu qnurdqowqn (nystqetoiq, 33.3 - 61.4) View more
NCT03523819 (ESMO_IO 12021 \| ESMO_IO 22021) Manual	Phase 1	HR-positive/HER2-low Solid Tumors	36	CS1002+CS1003 (MSI-H/dMMR tumors or MEL + arm A)	bwctjmudpd(knfplnglru) = 5 (9.3%) pts had AEs leading to discontinuation of CS1002 and CS1003. rbycbuhsnr (cbypmhhffv ) View more	Positive	09 Dec 2021
				CS1002+CS1003 (MSI-H/dMMR tumors or MEL + arm B)
NCT03523819 (ESMO 12021 \| ESMO 22021) Manual	Phase 1	HR-positive/HER2-low Solid Tumors	33	CS1003 200 mg+CS1002 0.3 mg/kg	izbfhmumja(mojefgrvjw) = Two (6.1%) pts experienced AEs leading to discontinuation of CS1002 and CS1003. rurbswzmfc (hwcdyuxeuq )	Positive	16 Sep 2021
				CS1003 200 mg+CS1002 1 mg/kg

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis